2024
Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.
Fischbach N, Zhou B, Deng Y, Parsons K, Shelton A, Lustberg M. Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer. Journal Of Clinical Oncology 2024, 42: e24140-e24140. DOI: 10.1200/jco.2024.42.16_suppl.e24140.Peer-Reviewed Original ResearchStage I-III breast cancerI-III breast cancerAdverse breast cancer outcomesBreast cancerMaximal weight lossMean weight lossBreast cancer survivorsDistant breast cancer recurrenceGLP-1 agonistsBreast cancer outcomesStage distributionClinically meaningful weight lossBreast cancer recurrenceWeight loss maintenanceUntreated patientsCancer survivorsMeasures regression analysisIncidence of diabetesWeight lossTreated patientsRetrospective analysisHealth NetworkMental healthCancer outcomesGLP-1
2023
1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis
SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.Peer-Reviewed Original ResearchGlucagon-like-peptide-1 agonistsFollow-upAmerican Diabetes AssociationType 2 diabetesManagement of T2DDiverse cohort of youthReduced doses of insulinMonths of follow-upMulticenter retrospective analysisGlucagon-like-peptide-1High risk of diabetic complicationsGLP-1 agonistsRisk of diabetic complicationsDoses of insulinPediatric diabetes centersBaseline to follow-upAssociated with improvementsMetformin usePharmacological optionsReduced dosePediatric populationPrandial insulinPrescribed metforminRetrospective analysisNational Institutes of Health
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply